Bigul

PANACEA BIOTEC LTD. - 531349 - Disclosure Under Regulation 30 Read With Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Non Exercise Of Option To Convert The Warrants Into Equity Shares

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that since the Warrant Holders did not exercise the conversion option within the aforesaid period, the Warrants stand cancelled / lapsed and the upfront amount of Rs.31,99,99,995/- (equivalent to 25% of total consideration) as received by the Company from the Warrant Holders, towards allotment of the said Warrants stands forfeited in accordance with the terms of the said Warrants and as per the provisions of Regulation 169(3) of Chapter V of SEBI ICDR Regulations
08-10-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 For The Half-Year Ended On September 30, 2020

Pursuant to the provisions of Regulation 7(3) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we are enclosing herewith the certificate duly signed by Skyline Financial Services Pvt. Ltd., Share Transfer Agent and Company Secretary of Panacea Biotec Ltd. for the half year ended on September 30, 2020 in compliance of Regulation 7(2) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
07-10-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, the details of Shares dematerialized during September, 2020 are enclosed herewith
07-10-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

We would like to inform you that pursuant to the Scheme, the Resulting Company in its Board Meeting held on October 06, 2020 has issued and allotted 6,12,50,746 Equity Shares of Re.1 each and 1,63,000 0.5% cumulative non-convertible and non-participating redeemable preference shares of Rs.10/- each to the equity and preference shareholders of the Company, respectively, whose names appeared in the register of members / record of the depositories as a beneficial owner as on the Record Date i.e. September 22, 2020. The new Equity Shares issued & allotted by Resulting Company to the shareholders of the Demerged Company in accordance with the Scheme shall be listed and/or admitted to trading on the BSE Limited and National Stock Exchange of India Limited (NSE), subject to requisite approvals of Exchanges/SEBI.
06-10-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Closure of Trading Window

Pursuant to the Company''s Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all the Designated Persons of the Company and Material Subsidiaries of the Company from October 01, 2020 till completion of 48 hours from the announcement to the Stock Exchanges regarding Unaudited financial results of the Company for the quarter and half year ended September 30, 2020. The date of meeting of the Board of Directors to approve the Unaudited financial results of the Company for the quarter and half year ended September 30, 2020, shall be informed in due course.
30-09-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Clarifies on news item

With reference to news appeared in bloombergquint.com dated September 30, 2020 quoting "Panacea Biotech Ltd Baddi facility received a warning letter from the U.S. FDA .", Panacea Biotec Ltd has submitted to BSE a copy of Clarification is enclosed.
30-09-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Clarification sought from Panacea Biotec Ltd

The Exchange has sought clarification from Panacea Biotec Ltd on September 30, 2020, with reference to news appeared in bloombergquint.com dated September 30, 2020 quoting "Panacea Biotech Ltd Baddi facility received a warning letter from the U.S. FDA ."The reply is awaited.
30-09-2020
Bigul

Panacea Biotec gains 5% on successful dengue vaccine trial

Panacea Biotec on Thursday announced the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, Dengi
24-09-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Re.: Press Release - Successful completion of Phase I/II study of its novel, Tetravalent recombinant chimeric Dengue candidate vaccine, DengiAll Panacea Biotec Ltd. ('PBL') is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose live-attenuated tetravalent vaccine. A copy of the Press Release titled 'Panacea Biotec announces successful completion of Phase I/II study of its novel, Tetravalent recombinant chimeric Dengue candidate vaccine, DengiAll' being issued to the media, etc. in this regard is enclosed for your kind reference and record please
24-09-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sunanda Jain
21-09-2020
Next Page
Close

Let's Open Free Demat Account